How do you design a value-based contract for a new gene therapy?
Gene therapies offer the potential to cure or significantly improve the lives of patients with rare and serious diseases. However, they also pose major challenges for payers, providers, and manufacturers in terms of pricing, reimbursement, and value assessment. One way to address these challenges is to design a value-based contract (VBC) that links the payment to the outcomes and evidence of the gene therapy. In this article, you will learn how to design a VBC for a new gene therapy using six steps.
-
Girisha FernandoCEO & Founder LYFEGEN | Creating the future of drug access, pricing and rebates with software 🇨🇭🇺🇸 based
-
Jaap De BoerPursuing Passion in Rare Neuro-musculair diseases
-
Paola ValinottiPatient & Market Access Leader, Advisor and Coach | Empowering organizations to accelerate PEOPLE access to healthCARE.